Clinuvel Pharmaceuticals (CUV)

Download button icon Download

Clinuvel Pharmaceuticals (CUV): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY

Clinuvel Pharmaceuticals (CUV.AX)


Indicator:

ULCER INDEX


Last Signal:

BULLISH


Trading: BUY @ $19.19
Signal Strength: MEDIUM
Recommendation:

Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.


Clinuvel Pharmaceuticals (ASX:CUV) UIX index implies that the downside risk of the current trading price is high. Currently, the UIX is 15.315.



A technical indicator that measures downside risk in terms of both depth and duration of price declines. The Ulcer Index (UI) increases in value as the price moves farther away from a recent high and falls as the price rises to new highs. The indicator is usually calculated over 14 days with the UI showing the percentage drawdown a trader can expect from the high over that period. The greater the value of the UI the longer it takes for a stock to get back to the former high.

Calculation: Ulcer Index:
1) Percentage Drawdown = [(Close - 14-period High Close)/14-period High Close] x 100;
2) Squared Average = (14-period Sum of Percentage Drawdown Squared)/14;
3) Ulcer Index = Square Root of Squared Average;


PROFILE: Clinuvel Pharmaceuticals (CUV.AX)


Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |

About Clinuvel Pharmaceuticals (ASX:CUV):

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.

Top 10:

Ulcer Index

Download button icon Download
Company Close Change (%) Volume Value Signal
HSO Healthscope 2.38 14.4 40,437,560 1.79 BULLISH
FLN Freelancer 0.88 12.9 1,312,856 2.54 BULLISH
MNS Milnes Holdings 0.37 12.3 2,277,569 2.58 BULLISH
LYC Lynas Corporation 2.4 9.6 12,451,685 1.06 BULLISH
LYL Lycopodium 5 8.7 110,499 2.08 BULLISH
TZN Terramin Australia 0.13 8.3 220,506 1.18 BULLISH
CVW Clearview Wealth 0.96 7.9 88,268 2.61 BULLISH
OMH OM Holdings 1.49 7.2 432,734 1.66 BULLISH
LVH Livehire 0.41 6.5 443,661 4.45 BULLISH
VTG Vita 1.14 6.5 609,580 3.02 BULLISH
back to top